A Biotech Company Wants to Dilute Its Stock by 951% to Buy Crypto Instead of Funding Its Own Drug — Here's What That Means
5h ago · 1 source
A biotech company is asking shareholders to approve a massive stock dilution of 951% in order to accumulate an illiquid cryptocurrency token, rather than using the capital to fund its core pharmaceutical research and development. The move raises serious questions about corporate governance, fiduciary duty, and the growing trend of companies pivoting to crypto treasury strategies.
WHY IT MATTERS
Imagine you co-own a bakery with friends, and the manager suddenly says, 'Let's print 10 times more ownership shares and use the money to buy a rare collectible coin that's hard to sell — instead of buying a new oven.' That's essentially what's happening here. Stock dilution means existing shareholders' pieces of the pie get much smaller. An 'illiquid' token means it's hard to buy or sell without moving the price significantly — like trying to sell a house in a ghost town. This matters because it shows how some companies are using crypto hype to justify risky financial decisions that may not benefit their actual investors, and it could lead to stricter rules for how public companies interact with crypto.
Read the full analysis with a CryptoBipto membership
Create a free account and subscribe to unlock deep-dive analysis on every story.
Get startedSOURCES
RELATED
Educational only — not financial advice.